CCL2 and chronic kidney disease: Specifically, increases in urine KIM-1, MCP-1, and plasma TNFR1 from baseline to 12 months correlated with a 2- to 3-fold increased risk of CKD, while an increase in urine uromodulin was associated with a 40% reduced risk [44].